Dermatology
| Hidradenitis Suppurativa
Dermatology
Hidradenitis Suppurativa
Ruxolitinib cream for mild-to-moderate hidradenitis suppurativa: 32-week data from a randomized phase 2 study
book_2
Source:
EADV 2024 - Oral session
calendar_today
Published on Medfyle:
October 2024
import_contacts
5
min
In this medfyle
A late-breaking abstract from EADV 2024, sharing 32-week data from a randomised Phase 2 study of topical ruxolitinib in people with mild-to-moderate hidradenitis suppurativa. As-needed application gave sustained or improved clinical signs and was generally well tolerated.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Infomedica-Medfyle. All rights reserved.
Source: Ruxolitinib cream for mild-to-moderate hidradenitis suppurativa: 32-week data from a randomized phase 2 study. Porter ML, et al. Presented at EADV 2024; Abstract #8071.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
